Navigation Links
BioMarin to Present at the Jefferies Healthcare Conference
Date:6/10/2009

NOVATO, Calif., June 10 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Senior Vice President and Chief Business Officer of BioMarin, will present a company update at the Jefferies Healthcare Conference in New York City on Wednesday, June 17, 2009 at 8:30 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin to Present at the Goldman Sachs Healthcare Conference
2. BioMarin to Present at the Deutsche Bank Health Care Conference
3. BioMarin to Present at the Baird Growth Stock Conference
4. BioMarin Announces First Quarter 2009 Financial Results
5. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
6. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
7. BioMarin to Present at the 4th Annual Citi Biotech Day
8. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
9. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
10. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
11. BioMarin to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015  Together with its customers, Elekta ... Forum in Barcelona . The funds ... with the mission to improve cancer care, specifically radiation ... believes that no patient should be denied potentially life-saving ... it cooperates with hospitals and clinics around the world ...
(Date:4/24/2015)... California (PRWEB) April 24, 2015 ... key milestones in its allogeneic stem-cell product development ... to properly reflect the corporate strategic direction. , ... allogeneic (donor) adipose stem cell development program has ... of our cGMP manufacturing facility and hiring of ...
(Date:4/24/2015)... N.J. , April 24, 2015  Navitas Life Sciences ... as Head of Clinical and Regulatory Services. Shalabh is ... been a co-founder and CEO of Kinapse, as well as ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome Shalabh ...
(Date:4/23/2015)... 23, 2015 The Thomas Brain ... conduct a groundbreaking pilot study to see if ... in as little as three to six months. ... and nutritional medicine—will aggressively target and simultaneously treat ... our aging brain. These include oxidative stress, neuroinflammation, ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... YORK, Aug. 10 ExL Pharma is pleased ... many of the leading issues that are,impacting the ... offer educational and networking opportunities for Clinical,Marketing, R&D, ... biotech and medical technology companies. Listed below ...
... Genmab,s Partner Roche has Filed an IND With the US FDA for ... ... A/S (OMX: GEN),announced today that its partner Roche has filed an Investigational ... antibody developed under the companies, collaboration. Genmab will,receive a milestone payment from ...
... Reliant Pharmaceuticals,Inc. today announced that it has filed ... Exchange Commission for an initial public offering,of its common ... issued common stock and that certain stockholders may sell,a ... Goldman, Sachs & Co. and Merrill Lynch & ...
Cached Biology Technology:Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up! 2Roche Files IND for Second Genmab Antibody 2Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering 2
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... as a folk remedy, but now scientists from Britain and ... as a treatment for herpes. The team,s findings, published in ... between two teams to established scientific evidence for traditional medicines. ... across mainland Europe and Asia. From the Middle Ages onwards ...
... OAK RIDGE, Tenn, Feb. 22, 2011 -- A theoretical ... National Laboratory is bringing supercomputer simulations and experimental results ... ORNL,s Jeremy Smith collaborated on devising a method -- ... experiments and computer simulations to strengthen analyses of molecules ...
... Conservation Society (WCS) working in conjunction with the Turtle ... from around the world some of which currently ... hunting for both food and the pet trade along ... in the next decade unless drastic conservation measures are ...
Cached Biology News:Old folk remedy revived: How tansy may be a treatment for herpes 2'Fingerprints' match molecular simulations with reality 2Shellshock: New report lists 25 most endangered turtle species 2
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Request Info...
Biology Products: